Tumor cells have decreased ability to metabolize H(2)O(2): Implications for pharmacological ascorbate in cancer therapy

Ascorbate (AscH(−)) functions as a versatile reducing agent. At pharmacological doses (P-AscH(−); [plasma AscH(−)] ≥≈20 mM), achievable through intravenous delivery, oxidation of P-AscH(−) can produce a high flux of H(2)O(2) in tumors. Catalase is the major enzyme for detoxifying high concentrations...

Descripción completa

Detalles Bibliográficos
Autores principales: Doskey, Claire M., Buranasudja, Visarut, Wagner, Brett A., Wilkes, Justin G., Du, Juan, Cullen, Joseph J., Buettner, Garry R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106370/
https://www.ncbi.nlm.nih.gov/pubmed/27833040
http://dx.doi.org/10.1016/j.redox.2016.10.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106370/
https://www.ncbi.nlm.nih.gov/pubmed/27833040
http://dx.doi.org/10.1016/j.redox.2016.10.010

Ejemplares similares